Skip to main content
. 2022 Apr 18;53(4):423–430. doi: 10.1016/j.arcmed.2022.04.003

Table 4.

Treatment-related adverse events stratified by treatment groupsa

Account (%)
Adverse event VDG n = 150 PG n = 152 pb
Any treatment-related adverse event 46 (30.7) 48 (31.6) 0.864
Headache 8 (5.3) 18 (11.8) 0.044
Constipation 15 (10.0) 7 (4.6) 0.071
Diarrhea 7 (4.7) 8 (5.3) 0.811
Nausea 7 (4.7) 3 (2.0) 0.191
Abdominal pain 5 (3.3) 2 (1.3) 0.244
Dizziness 3 (2.0) 6 (3.9) 0.320
Drowsiness 9 (6.0) 9 (5.9) 0.977
Muscular weakness 6 (4.0) 8 (5.2) 0.602
Vomiting 1 (0.7) 0 (0) 0.313
a

Values are n (%);

b

Statistics was conducted with χ2 analysis.